Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Based on its improved safety profile, capecitabine has the potential to replace 5-FU/LV as standard adjuvant treatment for patients with colon cancer.

Oral Capecitabine as an Alternative to IV 5-fluorouracil-Based Adjuvant Therapy for Colon Cancer: Safety Results of a Randomized, Phase III Trial